News Sentiment

MAZE sentiment intelligence

Maze Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 30.57 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-2.2% over one week, +27.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

$MAZE stock is down 10% today. Here's what we see in our data.

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction -2.2% Price reacting lower
Trend fit Trend inactive 27.1% over four weeks
Fair value 23.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 41
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 10
TradingView 10
Quiver Quantitative 3
Investing.com 2
simplywall.st 2
Seeking Alpha 2
TIKR.com 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 19
Balance sheet 1
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Stock Titan Direct company coverage

[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised stock options to acquire 14,609 shares and subsequently sold all of them in open market transactions on July 1, 2026. The sales were executed at weighted average prices of $29.8650 and $30.3369 per share under

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 03:40
Source
Stock Titan
Stock Titan Direct company coverage

Maze Therapeutics (MAZE) CEO’s family trusts sell 34,501 shares under 10b5-1 plan

Family trusts associated with Maze Therapeutics (MAZE) CEO Jason V. Coloma sold a total of 34,501 shares of common stock on July 1, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, were reported at weighted average pric

Tone
Negative 38/100
Event
Market update
Published
02 Jul 2026 20:39
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Maze Therapeutics, Inc. – NASDAQ:MAZE

This article focuses on the enterprise value to EBITDA forward for Maze Therapeutics, Inc. (NASDAQ: MAZE). It appears to be a financial data page from TradingView, providing financial metrics and market information for the company. The content includes details like market status,

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 07:14
Source
TradingView
Stock Titan Direct company coverage

MAZE (NASDAQ: MAZE) sale notice: 46,892 shares via option exercise

Maze Therapeutics, Inc. (NASDAQ: MAZE) has filed a Form 144 notice for the proposed sale of 46,892 common shares, scheduled for July 1, 2026, through the exercise of stock options with cash proceeds. The filing also reports two previous 10b5-1 sales by Harold Bernstein totaling 2

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 21:09
Source
Stock Titan
Investing.com Direct company coverage

Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares

Atul Dandekar, CSBO at Maze Therapeutics (NASDAQ:MAZE), sold 7,500 shares for $210,150 on June 29, 2026, while simultaneously acquiring 7,500 shares through stock options for $78,150. These transactions were conducted under a Rule 10b5-1 trading plan. Following these moves, Dande

Tone
Negative 38/100
Event
Market update
Published
01 Jul 2026 21:09
Source
Investing.com
Stock Titan Direct company coverage

MAZE (MAZE) trusts sell tens of thousands of common shares May–June 2026

MAZE Therapeutics, Inc. (MAZE) reported through a Form 144 filing that related trusts, specifically the Coloma Family Trust and the Coloma 2021 Irrevocable Trust, sold common shares between May and June 2026. The filing details multiple transactions including share counts and sal

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Maze Therapeutics (MAZE) CSBO sells 7,500 shares under Rule 10b5-1 plan

Maze Therapeutics CSBO Atul Dandekar exercised 7,500 stock options at $10.42 per share and subsequently sold 7,500 shares of common stock at $28.02 per share. These transactions, totaling $210,150, were conducted on June 29 under a pre-arranged Rule 10b5-1 trading plan. Following

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of Maze Therapeutics, Inc. – NASDAQ:MAZE

This article provides a financial snapshot of Maze Therapeutics, Inc. (NASDAQ: MAZE), focusing on its forward price-to-earnings ratio. It indicates that no trades were made and the market is currently closed for the company. The content also lists various financial and analytical

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Maze Therapeutics, Inc. – NASDAQ:MAZE

This page provides financial information for Maze Therapeutics, Inc. (NASDAQ: MAZE), focusing on its enterprise value to revenue forward. The content appears to be from TradingView, offering an overview of the company's financial data.

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 02:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Maze Therapeutics, Inc. – BOATS:MAZE

This article provides financial information for Maze Therapeutics, Inc. (MAZE) on the TradingView platform. It specifically focuses on the company's "Price to book forward" metric. The content highlights the financial data provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Maze Therapeutics, Inc. – BOATS:MAZE

This page displays information regarding the Price to Sales Forward metric for Maze Therapeutics, Inc. (BOATS:MAZE) on the TradingView platform. It indicates that the market is currently closed with no trades. The core content shows a "Period Value Change Change %" section, likel

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 06:40
Source
TradingView
Sahm Direct company coverage

Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In?

Maze Therapeutics (MAZE) has seen a significant rebound, with its stock up 5.2% in the past day and 10.7% over the past week, despite being down 28.51% year to date. The company trades at a Price to Book (P/B) ratio of 4.6x, indicating a higher valuation than the broader US pharm

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:39
Source
Sahm
TradingView Direct company coverage

MAZE Forecast — Price Target — Prediction for 2027

This article provides an in-depth forecast and analysis for Maze Therapeutics, Inc. (MAZE) stock, including current price, analyst ratings, price targets, historical performance, earnings data, and future revenue expectations. It also answers frequently asked questions about MAZE

Tone
Positive 72/100
Event
Earnings
Published
27 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

Maze Therapeutics, Inc. Actuals & Estimates (NASDAQ:MAZE)

This article provides an analysis of Maze Therapeutics, Inc. (NASDAQ: MAZE) stock, covering current price, market capitalization, historical performance, and future forecasts from analysts. It highlights that MAZE stock has shown significant growth over the last year and includes

Tone
Positive 76/100
Event
Market update
Published
26 Jun 2026 11:39
Source
TradingView
Stock Titan Direct company coverage

Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan

Maze Therapeutics CEO Jason V. Coloma indirectly sold 27,858 shares of common stock through family trusts at an average price of approximately $26 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 6, 2026, indicating they were

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 02:10
Source
Stock Titan
TradingKey Direct company coverage

Maze Therapeutics Inc (MAZE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Maze Therapeutics Inc.'s (MAZE) dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no recorded stock split events. The page also presents current stock performance d

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 23:10
Source
TradingKey
Stock Titan Direct company coverage

Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options

Richard H. Scheller, a director at Maze Therapeutics, has been granted 18,000 stock options with an exercise price of $23.58 per share, expiring on June 7, 2036. This compensation-related grant will vest on the earlier of the company's 2027 annual stockholders meeting or June 8,

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 19:09
Source
Stock Titan
Stock Titan Direct company coverage

Director Lim receives 18,000 Maze (MAZE) options vesting by 2027

Maze Therapeutics director Jonathan E. Lim was granted 18,000 stock options with an exercise price of $23.58 per share. These options will vest and become fully exercisable by the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, provided Lim continues hi

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 19:09
Source
Stock Titan
Stock Titan Direct company coverage

Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58

Maze Therapeutics director Herve Hoppenot was granted 18,000 stock options with an exercise price of $23.58 per share. These options, granted on June 8, 2026, will vest fully on the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, contingent on his conti

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 19:09
Source
Stock Titan
Stock Titan Direct company coverage

18,000 Maze Therapeutics (MAZE) options granted to director Andrews

Maze Therapeutics director Nancy C. Andrews was granted 18,000 stock options with an exercise price of $23.58 per share, expiring on June 7, 2036. The options will vest on the earlier of the company's 2027 annual stockholders meeting or June 8, 2027, contingent on her continued s

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 18:39
Source
Stock Titan